In the last trading session, 1.01 million Aclaris Therapeutics Inc (NASDAQ:ACRS) shares changed hands as the company’s beta touched 0.39. With the company’s per share price at $4.07 changed hands at $0.25 or 6.54% during last session, the market valuation stood at $309.75M. ACRS’s last price was a discount, traded about -27.03% off its 52-week high of $5.17. The share price had its 52-week low at $0.80, which suggests the last value was 80.34% up since then. When we look at Aclaris Therapeutics Inc’s average trading volume, we note the 10-day average is 10.52 million shares, with the 3-month average coming to 2.17 million.
Analysts gave the Aclaris Therapeutics Inc (ACRS) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.57. If we narrow down to specifics, the data shows that 1 out of 4 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended ACRS as a Hold, 3 felt it is a Buy and 0 rated the stock as Underweight.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Aclaris Therapeutics Inc (NASDAQ:ACRS) trade information
Instantly ACRS was in green as seen at the end of in last trading. With action -5.79%, the performance over the past five days has been red. The company’s shares are showing year-to-date upside of 287.62%, with the 5-day performance at -5.79% in the red. However, in the 30-day time frame, Aclaris Therapeutics Inc (NASDAQ:ACRS) is 126.11% up. Looking at the short shares, we see there were 1.56 million shares sold at short interest cover period of 1.43 days.
The consensus price target for the stock as assigned by Wall Street analysts is 7.5, meaning bulls need an upside of 45.73% from its current market value. According to analyst projections, ACRS’s forecast low is 3 with 25 as the target high. To hit the forecast high, the stock’s price needs a -514.25% plunge from its current level, while the stock would need to tank 26.29% for it to hit the projected low.
Aclaris Therapeutics Inc (ACRS) estimates and forecasts
Data shows that the Aclaris Therapeutics Inc share is performing relatively much better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot 295.15% over the past 6 months, a 51.61% in annual growth rate that is considerably higher than the industry average of 16.50%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 20.67%. The 2024 estimates are for Aclaris Therapeutics Inc earnings to increase by 41.73%.
ACRS Dividends
Aclaris Therapeutics Inc is expected to release its next quarterly earnings report in January.
Aclaris Therapeutics Inc (NASDAQ:ACRS)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 3.59% of Aclaris Therapeutics Inc shares while 90.28% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 93.64%. There are 90.28% institutions holding the Aclaris Therapeutics Inc stock share, with BML CAPITAL MANAGEMENT, LLC the top institutional holder. As of 2024-06-30, the company held 18.2739% of the shares, roughly 12.99 million ACRS shares worth $14.29 million.
VANGUARD GROUP INC holds the second largest percentage of outstanding shares, with 6.5952% or 4.69 million shares worth $5.16 million as of 2024-06-30.
